Hadassah Santa Cruz

08/22/2026

Tuesday 9/8

Three weeks to go. Two and a half years of testimony led to a report the world couldn’t ignore — now hear the story behind it.

Join us and on Tuesday, September 8 at 8:30 AM EST for a behind-the-scenes conversation with Cochav Elkayam-Levy and journalist Abigail Pogrebin.

Register now to save your spot. https://us02web.zoom.us/webinar/register/WN_vOVyhxNtRqmev0OH9PZoxQ #/registration

08/22/2026

This is Hadassah

A first in Israel. A new direction for treating a deadly brain cancer. 🧠

For the first time in Israel, neurosurgeons at the Hadassah Medical Organization have used intracranial Alpha DaRT® radiation therapy to treat a patient with recurrent glioblastoma — one of the most aggressive and difficult-to-treat brain tumors.

Led by Dr. Yigal Shoshan, HMO director of Neurosurgery, Oncology and Stereotactic Radiosurgery, the procedure is part of a Phase 1 clinical trial exploring a potentially new approach to treating recurrent glioblastoma.

What makes Alpha DaRT different? The technology delivers highly localized alpha radiation directly within the tumor, with the goal of maximizing tumor destruction while minimizing exposure to surrounding healthy brain tissue.

And in a world first, Dr. Shoshan and his team used two simultaneous trajectories to implant the radiation sources into a large tumor while maintaining precision.

This moment represents years of work — from laboratory research and preclinical studies to technological development and, now, clinical application.

“Seeing the technology reach a patient in Israel for the first time was an exciting moment for everyone who has been part of this journey,” said Dr. Shoshan.

It’s a powerful reminder of what can happen when research, technology and clinical expertise come together to pursue new possibilities for patients.

Tap the link in the comment section to read the full story.

08/21/2026

Lifechanging

He had bought a ticket to Switzerland to end his suffering. Then Hadassah gave him a reason to tear it up.

For years, this man with multiple myeloma endured debilitating pain and severe itching. Conventional treatments had failed, and relief seemed out of reach.

But Dr. Yuval Tal, director of the Allergy and Clinical Immunology Unit at Hadassah Hospital Ein Kerem, saw another possibility.

“The failure of standard treatments did not mean that all options had been exhausted.”

Dr. Tal and his team looked beyond the usual treatments and focused on the biological mechanisms behind the patient’s symptoms. Their approach led to an unexpected treatment: omalizumab, an antibody therapy typically used for severe allergies and asthma.

Within weeks of three injections, the patient’s pain and itching improved dramatically. He was able to reduce many of his pain medications — and most remarkably, he tore up his ticket to Switzerland.

A treatment that began with a question became a new reason for hope.

At Hadassah, when one path ends, our doctors keep looking for another.

Tap the link in the comment section to read the full story.

08/19/2026

Thank you, Hadassah

08/19/2026

Who knew?

Weird how the only "ethnostate" has the highest religious diversity.

08/19/2026

You never know where the journey will lead you. Thank you Hadassah

From the blog of Anastasia Torres-Gil at The Times of Israel

08/19/2026

For once, I don’t want to be #1

FBI data shows that Jews were targeted in 1,528 hate crimes in the US in 2025.

The figure amounts to 63% of all religion-based hate crimes in the US last year, the Anti-Defamation League says in its response to the data.

Read more on The Times of Israel.

https://www.timesofisrael.com/liveblog_entry/63-of-religious-hate-crimes-in-us-last-year-targeted-jews-fbi-data/

08/18/2026

Hebrew University scientists have successfully engineered a plant to produce beta-casein, a milk protein that helps give cheese its melting properties, which they believe puts them on the way to beating international competition to produce plants that can literally be milked at an industrial scale.

Read more on The Times of Israel.

https://www.timesofisrael.com/milk-from-seeds-israeli-scientists-produce-key-dairy-protein-from-safflower-plant/

08/16/2026

❤️

08/16/2026

Each action only takes 30 seconds to do

🚨 ACTION ALERT: Six Jewish California - formerly JPAC priority bills are at a critical stage in Sacramento, and we need your voice to help move them forward next week.

ACTION 1: Urge the Senate Appropriations Committee to advance five priority bills protecting safe worship, strengthening nonprofit security, supporting religious observance, ensuring equal access to public events, and combating hate.

👉 Take action: https://secure.everyaction.com/9cf0xQ8gwUCTajlgPQTEoA2

ACTION 2: Urge the Assembly Appropriations Committee to advance SB 1387, which recognizes Jewish identity as an ethnicity in California law and demographic data.

👉 Take action: https://secure.everyaction.com/SBBajk72-UOqIWMokP5l3Q2

Each action takes less than 30 seconds. Make your voice heard and share with your community!